StockData
ICU Medical Inc logo

ICU Medical Inc (ICUI) stock analysis

ICUINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3032% above fair value
$178.26−3.85 (-2.11%)

Close on Nov 11, 2026Market cap $4.46BP/E 74.0Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value2Growth2Performance3Health2Dividend0

Mixed9 of 30 checks passed

ICU Medical passes 9 of the 30 checks behind our score; 9 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
2/6
Growth
2/6
Past performance
3/6
Financial health
2/6
Dividend
0/6

What stands out

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 24.2% of total debt.

  • Guidance raised

    ICU Medical raised its Fiscal Year 2026 GAAP net income outlook on Aug 6, 2026.

  • EV/EBITDA below its 5-year median

    ICU Medical's EV/EBITDA of 17.1 is below its 5-year median of 19.2.

  • P/B below the industry

    ICU Medical's price-to-book of 2.03 is below the Surgical, Medical, and Dental Instruments and Supplies median of 3.22.

What to watch

  • Margin of safety under 20%

    The price is 32.2% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $178.26 is above our fair value estimate of $134.86.

  • Return on equity under 15%

    Return on equity was 2.8% over the last twelve months and averaged -0.9% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 3.6%, below the 10% that usually covers the cost of capital.

Valuation2/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E above the industry

    ICU Medical's P/E of 74.0 is above the Surgical, Medical, and Dental Instruments and Supplies median of 27.7.

  • EV/EBITDA below its 5-year median

    ICU Medical's EV/EBITDA of 17.1 is below its 5-year median of 19.2.

  • P/B below the industry

    ICU Medical's price-to-book of 2.03 is below the Surgical, Medical, and Dental Instruments and Supplies median of 3.22.

  • Trading above fair value

    The share price of $178.26 is above our fair value estimate of $134.86.

  • Margin of safety under 20%

    The price is 32.2% above fair value, so there is no margin of safety.

Growth2/6
  • Revenue growing under 10% a year

    Revenue grew -0.7% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -5.9% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

  • Guidance raised

    ICU Medical raised its Fiscal Year 2026 GAAP net income outlook on Aug 6, 2026.

  • Gross margin improving

    Gross margin was 40.3% over the last twelve months, against 36.5% a year earlier.

Past performance3/6
  • Return on equity under 15%

    Return on equity was 2.8% over the last twelve months and averaged -0.9% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 3.6%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    ICU Medical's return on equity of 2.8% is above the Surgical, Medical, and Dental Instruments and Supplies median of -31.3%.

  • Earnings shrank over 5 years

    Net income shrank 61.5% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 2.8% over the last twelve months, against a 5-year average of -0.3%.

  • Net margin above the industry

    ICU Medical's net margin of 2.8% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.

Financial health2/6
  • High debt

    Debt is 52.6% of shareholders' equity, above the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 24.2% of total debt.

  • Interest not well covered

    Operating income covers interest expense 1.4 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 2.37 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 2.66; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    ICU Medical has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Our estimate per share

$134.86

The share price is 32% above this estimate.

20%+ below
Near fair value
20%+ above
$178.26Price$134.86Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E27.7×–27.7×$66.7047%
EV/EBITDA17.9×19.2×16.7×$188.7641%
P/B2.5×1.8×3.2×$218.8512%
Earnings powerleft out, too far from the others9.9% cost of equity––$40.34–
Fair value$134.86100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Surgical, Medical, and Dental Instruments and Supplies median 27.7

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$42.79M
Value traded per 1% price move
$26.88M

Downside

Medium risk

Typical loss in a bad month
16.5%
Volatility (annualized)
36%
Sharpe ratio, 1 year
0.66
Beta to the S&P 500 (5Y)
1.00

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

36.8%+0.5 pts over 5 years

Operating margin

1.9%−5.8 pts over 5 years

Net margin

0.0%−6.8 pts over 5 years

See a number that looks wrong?